Language:

Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout

Journal of the American College of Cardiology, 2018-03, Vol.71 (9), p.994-1004 [Peer Reviewed Journal]

2018 American College of Cardiology Foundation ;Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 6, 2018 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2017.12.052 ;PMID: 29496000

Full text available

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout
Author: Kim, Seoyoung C. ; Neogi, Tuhina ; Kang, Eun Ha ; Liu, Jun ; Desai, Rishi J. ; Zhang, MaryAnn ; Solomon, Daniel H.
Subjects: Age Factors ; Aged ; Aged, 80 and over ; Allopurinol ; Allopurinol - therapeutic use ; cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - prevention & control ; Cerebral infarction ; Cohort Studies ; comparative safety research ; Confidence intervals ; Cytokines ; Disease ; Female ; Geriatrics ; Gout ; Gout - diagnosis ; Gout - drug therapy ; Gout - epidemiology ; Gout Suppressants - therapeutic use ; Government programs ; Health care ; Health risks ; Heart ; Heart attacks ; Heart diseases ; Heart failure ; Hospitals ; Humans ; Incidence ; Initiators ; Laboratories ; Male ; Males ; Medicare ; Medicare - trends ; Mortality ; Myocardial infarction ; Nursing homes ; Older people ; Patients ; Prescription drugs ; probenecid ; Probenecid - therapeutic use ; Rheumatism ; Risk ; Risk Factors ; Stroke ; Studies ; Subgroups ; Survival analysis ; United States - epidemiology ; Uric acid ; Uricosuric Agents - therapeutic use
Is Part Of: Journal of the American College of Cardiology, 2018-03, Vol.71 (9), p.994-1004
Description: Patients with gout are at an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke, and heart failure (HF). The authors conducted a cohort study to examine comparative CV safety of the 2 gout treatments—probenecid and allopurinol—in patients with gout. Among gout patients ≥65 years of age and enrolled in Medicare (2008 to 2013), those who initiated probenecid or allopurinol were identified. The primary outcome was a composite CV endpoint of hospitalization for MI or stroke. MI, stroke, coronary revascularization, HF, and mortality were assessed separately as secondary outcomes. The authors estimated the incidence rate and hazard ratio of the primary and secondary outcomes in the 1:3 propensity score–matched cohort of probenecid and allopurinol initiators. A total of 9,722 probenecid initiators propensity score–matched to 29,166 allopurinol initiators with mean age of 76 ± 7 years, and 54% males were included. The incidence rate of the primary composite endpoint of MI or stroke per 100 person-years was 2.36 in probenecid and 2.83 in allopurinol initiators with a hazard ratio of 0.80 (95% confidence interval: 0.69 to 0.93). In the secondary analyses, probenecid was associated with a decreased risk of MI, stroke, HF exacerbation, and mortality versus allopurinol. These results were consistent in the subgroup analyses of patients without baseline CV disease or those without baseline chronic kidney disease. In this large cohort of 38,888 elderly gout patients, treatment with probenecid appears to be associated with a modestly decreased risk of CV events including MI, stroke, and HF exacerbation compared with allopurinol. [Display omitted]
Publisher: United States: Elsevier Inc
Language: English
Identifier: ISSN: 0735-1097
EISSN: 1558-3597
DOI: 10.1016/j.jacc.2017.12.052
PMID: 29496000
Source: Freely Accessible Journals
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout

2018 American College of Cardiology Foundation ;Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 6, 2018 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2017.12.052 ;PMID: 29496000

Searching Remote Databases, Please Wait